ARCA biopharma (ABIO) Stock Price, News & Analysis

Company Overview

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.40 to $599.04
• 52-Week Range: N/A
• Volume: 290,800 shs
• Average Volume: 607,995 shs
• Market Capitalization: $34.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ABIO Stock Analysis - Frequently Asked Questions

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) announced its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) EPS for the quarter, topping the consensus estimate of ($341.28) by $292.32.

When did ARCA biopharma's stock split?

Shares of ARCA biopharma reverse split on Tuesday, September 3rd 2024.The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/04/2021
• Today: 6/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABIO
• CIK: 907654
• Web: arcabio.com
• Phone: (720) 940-2100
• Fax: 720-208-9261
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.34 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.18%
• Return on Assets: -19.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.61
• Quick Ratio: 26.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.25 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,507,000
• Free Float: 10,024,000
• Market Cap: $34.82 million
• Optionable: Optionable
• Beta: 0.91